Correlation Between Ashmore Emerging and Biotechnology Ultrasector

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Ashmore Emerging and Biotechnology Ultrasector at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ashmore Emerging and Biotechnology Ultrasector into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Ashmore Emerging Markets and Biotechnology Ultrasector Profund, you can compare the effects of market volatilities on Ashmore Emerging and Biotechnology Ultrasector and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ashmore Emerging with a short position of Biotechnology Ultrasector. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ashmore Emerging and Biotechnology Ultrasector.

Diversification Opportunities for Ashmore Emerging and Biotechnology Ultrasector

-0.23
  Correlation Coefficient

Very good diversification

The 3 months correlation between Ashmore and Biotechnology is -0.23. Overlapping area represents the amount of risk that can be diversified away by holding Ashmore Emerging Markets and Biotechnology Ultrasector Prof in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Biotechnology Ultrasector and Ashmore Emerging is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ashmore Emerging Markets are associated (or correlated) with Biotechnology Ultrasector. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Biotechnology Ultrasector has no effect on the direction of Ashmore Emerging i.e., Ashmore Emerging and Biotechnology Ultrasector go up and down completely randomly.

Pair Corralation between Ashmore Emerging and Biotechnology Ultrasector

Assuming the 90 days horizon Ashmore Emerging Markets is expected to under-perform the Biotechnology Ultrasector. But the mutual fund apears to be less risky and, when comparing its historical volatility, Ashmore Emerging Markets is 11.38 times less risky than Biotechnology Ultrasector. The mutual fund trades about -0.16 of its potential returns per unit of risk. The Biotechnology Ultrasector Profund is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest  6,788  in Biotechnology Ultrasector Profund on August 30, 2024 and sell it today you would earn a total of  107.00  from holding Biotechnology Ultrasector Profund or generate 1.58% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Ashmore Emerging Markets  vs.  Biotechnology Ultrasector Prof

 Performance 
       Timeline  
Ashmore Emerging Markets 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Ashmore Emerging Markets has generated negative risk-adjusted returns adding no value to fund investors. In spite of fairly strong fundamental indicators, Ashmore Emerging is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.
Biotechnology Ultrasector 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Biotechnology Ultrasector Profund has generated negative risk-adjusted returns adding no value to fund investors. In spite of fairly strong forward indicators, Biotechnology Ultrasector is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Ashmore Emerging and Biotechnology Ultrasector Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Ashmore Emerging and Biotechnology Ultrasector

The main advantage of trading using opposite Ashmore Emerging and Biotechnology Ultrasector positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ashmore Emerging position performs unexpectedly, Biotechnology Ultrasector can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biotechnology Ultrasector will offset losses from the drop in Biotechnology Ultrasector's long position.
The idea behind Ashmore Emerging Markets and Biotechnology Ultrasector Profund pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.

Other Complementary Tools

Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA